Roivant Sciences (NASDAQ:ROIV) Insider Frank Torti Sells 1,400,000 Shares

Roivant Sciences Ltd. (NASDAQ:ROIV) insider Frank Torti sold 1,400,000 shares of the stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $27.42, for a total transaction of $38,388,000.00. Following the completion of the sale, the insider owned 13,736,547 shares of the company’s stock, valued at approximately $376,656,118.74. The trade was a 9.25% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Frank Torti also recently made the following trade(s):

• On Friday, February 20th, Frank Torti sold 1,012,610 shares of Roivant Sciences stock. The stock was sold at an average price of $27.15, for a total value of $27,492,361.50.
• On Monday, February 23rd, Frank Torti sold 587,390 shares of Roivant Sciences stock. The shares were sold at an average price of $27.51, for a total value of $16,159,098.90.

Roivant Sciences Stock Up 2.2%

Shares of ROIV traded up $0.61 during midday trading on Monday, reaching $27.76. The company had a trading volume of 4,414,766 shares, compared to its average volume of 6,823,292. Roivant Sciences Ltd. has a 1-year low of $8.73 and a 1-year high of $27.94. The firm has a 50 day simple moving average of $23.44 and a 200-day simple moving average of $19.07.

Institutional Investors Weigh In On Roivant Sciences

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ROIV. Dorsey Wright & Associates acquired a new position in shares of Roivant Sciences during the fourth quarter worth about $8,162,000. Invesco Ltd. boosted its position in Roivant Sciences by 28.9% during the fourth quarter. Invesco Ltd. now owns 2,281,487 shares of the company’s stock worth $49,508,000 after purchasing an additional 512,129 shares in the last quarter. Mercer Global Advisors Inc. ADV purchased a new position in Roivant Sciences during the 4th quarter valued at about $227,000. Empowered Funds LLC purchased a new position in shares of Roivant Sciences during the 4th quarter worth approximately $396,000. Finally, VestGen Investment Management acquired a new position in shares of Roivant Sciences during the 4th quarter worth approximately $743,000. Hedge funds and other institutional investors own 64.76% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have commented on ROIV. Leerink Partners boosted their price target on shares of Roivant Sciences from $29.00 to $32.00 and gave the stock an “outperform” rating in a research note on Monday, December 15th. HC Wainwright lifted their price objective on Roivant Sciences from $26.00 to $33.00 and gave the company a “buy” rating in a research note on Tuesday, February 10th. TD Cowen restated a “buy” rating on shares of Roivant Sciences in a research note on Saturday, February 7th. Jefferies Financial Group reiterated a “buy” rating and issued a $30.00 price target on shares of Roivant Sciences in a research note on Monday, February 9th. Finally, Citigroup increased their price objective on shares of Roivant Sciences from $26.00 to $35.00 and gave the company a “buy” rating in a research report on Tuesday, February 10th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Roivant Sciences has an average rating of “Moderate Buy” and an average target price of $28.69.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.